Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis.
We previously showed that myasthenia gravis (MG) has a mild clinical expression when associated with autoimmune thyroid diseases (AITD). In the present study we have investigated the frequency of thyroid-associated ophthalmopathy (TAO) in patients with Graves' disease (GD) associated with MG as compared with GD patients without MG. A total of 418 patients with GD were studied, 31 with MG and 387 without MG. TAO was evaluated by physical examination, exophthalmometry, computerized tomography, and computerized visual fields assessment. The overall prevalence of TAO was similar in GD patients with MG (61.2%) and in those without MG (56.4%). When the analysis was restricted to GD patients with ocular MG, a greater frequency of TAO was found (84.6%), compared with GD patients without MG or with GD patients with generalized MG, although the differences did not reach the statistical significance. GD patients with MG had a significantly greater prevalence (12.9%) of euthyroid ophthalmopathy (clinically overt ophthalmopathy without previous and/or current hyperthyroidism) than those without MG (3.1%; p = 0.003). The results suggest a preferential association between the ocular manifestations of GD and MG, which may be due to immunological cross-reactivity against common autoimmune targets in the eye muscle as well as to a common genetic background.
Marinò
M
M
Department of Endocrinology, University of Pisa, Italy. m.marino@endoc.med.unipi.it
Barbesino
G
G
Pinchera
A
A
Manetti
L
L
Ricciardi
R
R
Rossi
B
B
Muratorio
A
A
Braverman
L E
LE
Mariotti
S
S
Chiovato
L
L
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications*; D013965:Thyroidectomy; D013974:Thyroxine / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014794:Visual Fields
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D008713:Methimazole; D013974:Thyroxine